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Cancer is the second most frequent cause of death,1 
with nearly half a million individuals in Brazil diagnosed 
with it every year.2 It has been suggested that efforts should 
be directed at increasing the amount of cancer research 
performed in Brazil, a country where the epidemiologic 
burden of the disease is not matched by a proportional 
increase in related research investments.3 Although the amount 
of cancer research is increasing in Brazil,4 there is a general 
impression that clinical research in particular is gaining 
substantial momentum. This is largely because pharmaceutical 
companies and contract research organizations have identified 
Brazil as an attractive site with rapid patient accrual and high 
quality data collection. Indeed, several recently published 
major oncology studies have included a substantial number 
of patients from Brazil, thus ensuring co-authorship of these 
articles to Brazilian investigators.5-9 
It would be interesting to investigate the extent to 
which the increase in research is related to projects that 
originate in Brazil, as opposed to instances in which a trial 
is conceived by international researchers with Brazilian 
investigators contributing to patient accrual. To that end, we 
analyzed Brazilian studies presented at American Society of 
Clinical Oncology (ASCO) Annual Meetings. This venue 
is considered the largest forum for oncology professionals 
from all over the world to report the latest advances in cancer 
research.10 Although the main focus of the meeting is on 
medical oncology, the ASCO Annual Meeting is a venue 
for research presentations in all areas of clinical oncology. 
On the other hand, studies on radiation oncology, surgical 
oncology, pediatric oncology, and hematologic malignancy, 
although frequently presented at ASCO Annual Meetings, 
have other important venues for presentation. 
We conducted a search of the 16,925 abstracts 
published in the Program Proceedings of the ASCO Annual 
Meetings from 2001 through 2005. Studies accepted by the 
meeting’s program committee may be presented in several 
forms, ranging from plenary and oral sessions to posters. 
Additionally, approximately 40% of the studies (termed 
“publication only”) only appear in the Program Proceedings. 
We defined Brazilian studies as those in which at least two-
thirds of the involved institutions were from Brazil. For cases 
in which there were two institutions and one of them was 
Brazilian, we decided by consensus whether the study also 
qualified as Brazilian. 
We identified 154 Brazilian studies (0.90%); the main 
characteristics of these studies are shown in Table 1. The 
number of Brazilian studies accepted by the program 
committee of the ASCO Annual Meeting between 2001 
and 2005 (Table 2) showed a statistically significant 
increase over the 5 year period (P=0.011). Support from the 
pharmaceutical industry was declared in seven abstracts, 
always in association with clinical studies. Two Brazilian 
studies were selected for oral presentation, 6 were selected 
for oral discussion by invited speakers (in “poster discussion” 
sessions), 41 were presented as posters, and 105 (68.2%) 
appeared as “publication only”. There was no statistically 
significant trend regarding the proportion of studies in the 
“publication only” category (P=0.407). 
Only 26 of the 154 studies (16.9%) were published in 
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full: 21 in journals indexed in Medline only, 3 in Lilacs 
only, and 2 in both databases. Twenty-one studies appeared 
in international journals, and 5 in Brazilian journals. The 
impact factor, available for 16 of the publications, had a 
median of 2.040 (range, 0.739 to 4.643). Figure 1 shows 
the Kaplan-Meier estimate of time to full publication. When 
only published papers are considered, the median time to 
publication was 13.5 months. Of the 26 published studies, 21 
(80.7%) appeared in print within 2 years from the presentation 
of the abstract. The low publication rate did not appear to 
be due to the short follow-up period, since these rates were 
16.7%, 30.7%, 15.2%, 9.3%, and 15.8% for 2001 through 
2005, respectively (P=0.323). Univariate analyses comparing 
abstracts according to both study type and support from the 
pharmaceutical industry suggested that these variables did not 
influence the probability of full publication. However, the type 
of presentation during the meeting had a log-rank P value of 
0.059 when “publication only” studies were compared with 
the other categories (Figure 2).
A potential limitation of our analysis is the fact that 
we only looked at studies presented at the ASCO Annual 
Meeting. Although quality studies may have been presented 
elsewhere, this seemed unlikely, at least for clinical studies, 
as other important meetings are less frequently attended by 
Brazilian investigators because such meetings either focus on 
specific tumors or are dedicated primarily to basic science. 
Moreover, radiation oncologists and pediatric oncologists 
are a smaller group compared with medical oncologists; 
therefore Brazilian scientific output in these two areas 
is probably smaller than that originating from medical 
oncologists. It is also conceivable that quality research 
Table 1 - Type and subject matter of Brazilian studies 
(N=154)
Study Characteristics N
Study type
     Clinical investigation 117
          Retrospective 43
          Phase II 37
          Unclassified prospective 24
          Phase I 4
          Randomized or phase III 2
          Other 44
     Basic science 23
     Epidemiologic study 14
Study subject
     Tumor biology 27
     Patient care 22
     Breast cancer 19
     Lung cancer 13
     Gastrointestinal cancer 13
     Genitourinary cancer 11
     Head and neck cancer 10
     Hematologic malignancy 5
     Pediatric oncology 8
     Other 26
Figure 1 - Time to publication of Brazilian studies initially presented in 
abstract form between 2001 and 2005 (tick marks represent censoring)
Figure 2 - Time to publication of Brazilian studies accepted for oral presenta-
tions, oral discussions and poster presentations, in comparison with abstracts 
in the “publication only” category (tick marks represent censoring)
Table 2 - Absolute number and proportion of Brazilian studies 
in the period 2001-2005
Year 2001 2002 2003 2004 2005
Brazilian 12 26 46 32 38
Total 3118 3024 3621 3554 3608
Percent 0.384862 0.859788 1.270367 0.900394 1.053215
P = 0.011
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reports originating in Brazil during these 5 years were 
submitted for full publication without prior presentation at 
the ASCO Annual Meeting. This appeared to be of greater 
concern only in the case of basic science and epidemiologic 
studies, given that clinical investigators are generally eager 
to present their data at the ASCO Annual Meeting.
Studies that are similar to ours have been conducted in 
the past. Goldman and Loscalzo described the fate of 276 
randomly selected cardiology abstracts presented at three 
meetings, and found that 49.6% of them were published in 
peer-reviewed journals within a period of 37 to 43 months.11 
In a study that evaluated abstracts presented at the 1984 
ASCO Annual Meeting, using a different methodology 
than ours, De Bellefeuille et al. found that 115 of 197 
abstracts (58%) accepted for the meeting led to full papers.12 
Publication rates have also been reported in radiology 
(35%13) and urology (37.8%14 to 47.3%15), among other 
disciplines. Compared with these studies,11-16 the publication 
rate of Brazilian abstracts presented at the ASCO Annual 
Meetings was low. A meta-analysis of 79 reports showed 
that only 44.5% of studies initially presented as abstracts 
or in summary form were published.17 Interestingly, this 
phenomenon of low publication rate is similarly seen for 
doctoral theses. Younes et al. reviewed the fate of 1,181 
doctoral theses presented to the University of Sao Paulo 
Medical School between 1990 and 2000, and found that 
more than 50% of investigators had not published their 
research within 5 years.18
The median interval between abstract presentation and 
full article publication ranged from 8.6 to 17 months,11,13,15,16 
with most of these studies published as full papers within 2 
years of abstract presentation.14-16 In this respect, our findings 
agreed with those from other investigators,11,13-16 suggesting 
that the time taken in submission, peer review and print was 
not an explanation for the low publication rate of Brazilian 
abstracts. 
We did not appraise the abstract content as it related to 
the study result, and were therefore unable to investigate 
the role of a positive result as a predictor of publication. We 
were also unable to assess support from the pharmaceutical 
industry as a possible predictor for publication. Such 
support was declared in only 4.5% of the abstracts in our 
study, which was not sufficient to provide enough power 
for analysis. However, sponsorship from the pharmaceutical 
industry has previously been reported to serve as an 
established predictor of publication of randomized trials 
presented at the ASCO Annual Meeting.19 
Our study provides insight into the current contribution 
of Brazilian studies to international cancer literature. 
Rodrigues et al. recently provided a quantitative summary 
of cancer research in Brazil by merging data from Medline 
and the Institute for Scientific Information.4 They found that 
Brazilian scientific output represented 0.28% of world cancer 
research in 1989 and 0.46% in 1994. In our study, Brazilian 
abstracts constituted 0.9% of all studies presented at the 
ASCO Annual Meetings from 2001 to 2005. Of note, Brazil 
did not appear in the list of the top 25 countries conducting 
clinical cancer research between 1995 and 1999.20
This analysis indicated an increase in Brazilian cancer-
related scientific output. But it also suggested that the 
quality of this research is still relatively low, given the high 
percentage of abstracts in the “publication only” category. 
Furthermore, only a small proportion of the Brazilian abstracts 
presented at the ASCO Annual Meeting were later published 
in indexed journals. Our approach serves as an attempt to 
answer a major underlying question: to what extent is cancer 
research conducted in Brazil relevant to Brazilian patients, 
investigators and society? This study represents a first step 
towards answering this important question, which should be 
followed by (amongst other things) the assessment of scientific 
presentations and publications by Brazilian cancer researchers 
in a broader perspective (e.g., doctoral theses, published 
studies regardless of prior abstract presentation, study retrieval 
from other databases, abstracts presented at other meetings, 
etc.). These results should be compared with those from other 
countries and disciplines by the appraisal of study quality, the 
potential existence of language barriers and other important 
issues. Although scientific research is clearly increasing in 
Brazil,21-24 with cancer research being one of the areas of 
increased output, we believe that Brazilian cancer researchers 
in general, and Brazilian clinical cancer researchers in 
particular, should strive to enhance the conception, design, 
analysis and reporting of studies that address questions which 
are relevant to our patients and our society.
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